Click HERE to register.

Join Suresh S. Ramalingam, MD, FACP, FASCO, Alexander Drilon, MD, and John Heymach, MD, PhD for this web broadcast. Experts will discuss the advances, new evidence, and best practices related to molecular testing and targeted treatment of NSCLC. Guidance for applying the emerging science to patient care decisions in everyday practice will also be shared, along with recommendations and resources for patient education and engagement in care decisions.

Activity Description

The targeted therapy landscape for non–small cell lung cancer (NSCLC) has evolved considerably in recent years, with far-reaching implications for oncologists, pathologists, and other members of the broader lung cancer care team, as well as for patients. This PeerView Live web broadcast will provide a comprehensive overview of the importance of performing genomic profiling to determine the optimal treatment approach for patients with molecularly altered NSCLC. In addition, essential practical guidance will be shared to help match targeted therapies to each patient’s genomic alteration for improved outcomes.

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists and other clinicians involved in the management of lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Evaluate the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of various molecular alterations in advanced/metastatic non–small cell lung cancer (NSCLC) in newly diagnosed patients and those with acquired resistance
• Characterize the mechanisms of action, safety/efficacy profiles, and indications of the various approved and investigational targeted therapies for NSCLC in different patient populations (eg, those targeting EGFR, ALK, BRAF, NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others)
• Integrate best practices related to molecular testing through the continuum of advanced NSCLC, and interpretation of results to guide treatment selection
• Educate patients with NSCLC and their caregivers about molecular testing and targeted therapy options to help them become well-informed participants in their care
• Implement evidence-based, individualized, precision treatment plans for management of molecularly altered NSCLC based on results of molecular testing, specific patient needs and preferences, and other key factors

Faculty

Chair

Suresh S. Ramalingam, MD, FACP, FASCO
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Presenters

Alexander Drilon, MD
Memorial Sloan Kettering Cancer Center
New York, New York

John Heymach, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Accreditation

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.